Kidney transplant rejection remains a significant challenge to long-term graft survival. While histological biopsy continues to be the gold standard for diagnosing rejection, noninvasive biomarkers such as donor-derived cell-free DNA (dd-cfDNA) have gained traction for their ability to detect allograft injury. However, dd-cfDNA may lack sensitivity in certain clinical scenarios particularly in cases of localized immune activation leading to false negatives despite biopsy-confirmed rejection.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Assess urinary CXCL10 compared to dd-cfDNA for diagnosing acute rejection in kidney transplant recipients
Timeframe: From date of inclusion until loss of follow-up, graft loss or death assessed up to 5 years.
Assess the stability of urinary CXCL10 under different transport conditions
Timeframe: From date of inclusion until loss of follow-up, graft loss or death assessed up to 5 years.